Welcome to our dedicated page for AKU news (Ticker: AKU), a resource for investors and traders seeking the latest updates and insights on AKU stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AKU's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AKU's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Akumin Inc. (NASDAQ: AKU) reported its Q4 and full-year 2022 financial results on March 16, 2023. The company achieved Q4 revenue of $184.6 million, a 3% increase year-over-year, and full-year revenue of $749.6 million, up 78% due to the Alliance HealthCare Services acquisition. However, net losses for Q4 and the year rose to $49.3 million and $151.6 million, respectively, primarily due to increased interest expenses and goodwill impairment charges. Adjusted EBITDA for Q4 was $37.4 million, marking a 36% increase. Akumin expects 2023 revenue between $765-775 million and Adjusted EBITDA of $150-160 million, highlighting ongoing transformation initiatives.
Akumin Inc. (NASDAQ: AKU) will host a conference call on March 17, 2023, at 8:30 a.m. ET to discuss its year-end 2022 financial results. These results will be available on March 16, 2023. The company provides diagnostic imaging and oncology services to nearly 1,000 hospitals across 48 states. Participants can access the call via a designated dial-in number or through a webcast. A replay will be available until March 24, 2023. Akumin focuses on enhancing patient diagnosis and treatment through advanced technology and operational expertise.
Akumin Inc. (NASDAQ: AKU) announced the appointment of John Wagner and Lawrence Ross Sinclair to its board of directors, effective January 1, 2023. Wagner, a co-founder of SCW Capital Management, brings significant investor confidence, holding about 12.7% of Akumin's stock. Sinclair, a former partner at PwC with over 25 years of experience, is set to join the audit committee. The appointments aim to enhance board expertise in finance and strategy, which could aid Akumin's growth and service delivery across its radiology and oncology solutions to 1,000 hospitals in 48 states.
